文献速递核素与放射性配体治疗放射性药物与辐射防护

炎症标志物与钬-166放射性栓塞治疗肝优势转移性神经内分泌肿瘤在初始肽受体放射性核素治疗后的长期血液毒性

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy.
PubMed 文献 · EJNMMI Res · 2022-02-02

本研究基于前瞻性HEPAR PLuS研究,分析肽受体放射性核素治疗(PRRT)后序贯钬-166放射性栓塞治疗肝转移神经内分泌肿瘤的血液毒性及中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(TLR)的预后价值。31例纳入毒性分析,30例纳入疗效分析;治疗后3周淋巴细胞计数显著下降(平均变化-0.26×10⁹/L),10例(32.2%)出现3-4级淋巴细胞毒性,6周和3个月时恢复。3周时NLR和TLR升高可显著预测3个月和6个月疗效,但与生存无显著关系。

要点

  • PRRT后序贯钬-166放射性栓塞的血液毒性有限且短暂,3-4级淋巴细胞毒性见于10例(32.2%)。
  • 治疗后3周淋巴细胞计数平均下降0.26×10⁹/L,6周和3个月时恢复。
  • 3周时NLR和TLR升高可预测3个月和6个月疗效,但与生存无显著关系。

核心结论

  • PRRT序贯钬-166放射性栓塞治疗的毒性有限且短暂,同时可预期显著的额外获益。
  • 3周随访时NLR和TLR的变化可能是疗效的有价值早期预测指标。

研究设计与样本

  • 纳入前瞻性HEPAR PLuS研究的所有患者,31例纳入毒性分析,30例纳入疗效分析。
  • 基线(放射性栓塞前)及1年随访期间定期进行血液检测。
  • 在3、6、9、12个月时根据RECIST 1.1评估影像学疗效。
  • 采用逻辑回归分析NLR和TLR对疗效的预后价值。

主要发现

  • 放射性栓塞后3周观察到淋巴细胞计数显著下降,平均变化-0.26×10⁹/L。
  • 10例患者(32.2%)出现3-4级淋巴细胞毒性。
  • 淋巴细胞毒性在治疗后6周和3个月时恢复正常,而6个月后观察到淋巴细胞计数显著增加。
  • 与基线相比,3周时NLR和TLR升高可显著预测3个月疗效(AUC分别为0.841和0.839)和6个月疗效(AUC分别为0.779和0.765)。
  • 未发现NLR和TLR与生存有显著关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [166Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT). The aim of this study was to analyze hematotoxicity profiles, (i.e. lymphocyte and neutrophile toxicity) and the prognostic value of neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR). METHODS: All patients included in the prospective HEPAR PLuS study were included in this study. Blood testing was performed at baseline (before radioembolization) and at regular intervals during 1-year follow-up. Radiological response was assessed at 3, 6, 9, and 12 months according to RECIST 1.1. Logistic regression was used to analyze the prognostic value of NLR and TLR on response. RESULTS: Thirty-one patients were included in the toxicity analysis; thirty were included in the response analysis. Three weeks after radioembolization, a significant decrease in lymphocyte count (mean change - 0.26 × 109/L) was observed. Ten patients (32.2%) experienced grade 3-4 lymphocyte toxicity. This normalized at 6 weeks and 3 months after treatment, while after 6 months a significant increase in lymphocyte count was observed. An increase in NLR and TLR at 3 weeks, compared to baseline, significantly predicted response at 3 months (AUC = 0.841 and AUC = 0.839, respectively) and at 6 months (AUC = 0.779 and AUC = 0.765). No significant relation with survival was found. CONCLUSIONS: Toxicity after sequential treatment with PRRT and [166Ho]-radioembolization is limited and temporary, while significant additional benefit can be expected. Change in NLR and TLR at 3-weeks follow-up may be valuable early predictors of response. Trial registration ClinicalTrials.gov, NCT02067988. Registered 20 February 2014, https://clinicaltrials.gov/ct2/show/record/NCT02067988 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ebbers SC, Brabander T, Tesselaar MET, et al. Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy. EJNMMI Res. 2022. PMID: 35107642. doi:10.1186/s13550-022-00880-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。